

Press release 2015-01-07

Medfield enters research cooperation in Australia

Medfield Diagnostics AB and Hunter Medical Research Institute, New South Wales (HMRI) have agreed to cooperate in research with microwave technology to diagnose abnormalities in the brain.

HMRI will facilitate research and studies to further explore the diagnostic possibilities using the microwave technology within the medical field. The intent of the studies is to publish findings that are beneficial for the handling of injuries and diseases in the brain, including but not limited to stroke. As part of this collaboration Medfield Diagnostics will allocate personnel to assist HMRI in analysing the results from the Strokefinder MD100 that HMRI will purchase.

- We firmly believe in this technology and see multiple opportunities how it can address diagnostic challenges that today lack adequate solutions, says professor Michael Nilsson, director of HMRI. Diagnosis of traumatic brain injuries is for sure one of these challenges.

- HMRI is a perfect partner for Medfield, both for their solid competence within relevant fields as well as for the drive and ambition to stay in the forefront when it comes to new technologies, comments Dag Jungenfelt, CEO of Medfield Diagnostics. This is yet another confirmation of the value of our Strokefinder-concept and may also be the first sale of MD100.

Questions may be addressed to Dag Jungenfelt, CEO Medfield Diagnostics AB, +46 70-987 28 27 or dag.jungenfelt@medfelddiagnostics.com

The Hunter Medical Research Institute (HMRI) is a translational medical research institute based in the Hunter Region of New South Wales, Australia. HMRI facilitates collaborations between researchers, translating scientific advances into better clinical care, competitive commercial products and improved health care guidelines. <http://www.hmri.com.au>

Kort om Medfield Diagnostics AB (publ)

Medfield Diagnostics har som mål att underlätta diagnostiseringen av en stroke. Om man på ett tidigt stadium kan avgöra om stroke beror på en blödning eller propp kan rätt behandling sättas in betydligt tidigare än idag. Därigenom elimineras mycket lidande hos drabbade patienter och det sparas mycket stora vård- och rehabiliteringskostnader för samhället. Medfields första produkt, Strokefinder R10, finns ute på marknaden och vänder sig till läkare och sjukhus som håller på med forskning inom stroke.

Medfield Diagnostics AB (publ)
Sahlgrenska Science Park
Medicinaregatan 8A
413 46 GÖTEBORG

Tel kontor: +46 (0)31 741 17 53
Web: www.medfelddiagnostics.com
e-post: info@medfelddiagnostics.com